Figure 7.

Dual specific CARs demonstrate ability to eliminate cancer cells in vivo

(A) NSG mice bearing OVCAR-3 derived tumors were treated at 5-day intervals with either 2 × 10⁶ T cells (no CAR), TAG-72.4-1BB CAR-T cells, TAG-72.4-1BB CAR + ΔCD47d CAR, or TAG-72.4-1BB CAR + ΔCD47m CAR by intravenous (i.v.) injection as soon as tumor volume (TV) was approximately 100mm³. (B) Tumor volume was monitored during 28 days. Data were generated from three independent experiments (and therefore three independent T cell donors) and are presented as raw tumor volume. (C) The ability for the aforementioned CAR-T cells to eliminate MESOV cells in vivo was also monitored. NSG mice bearing MESOV-derived tumors were treated as soon as palpable tumors were detected. (D) Tumor volume was monitored regularly during 28 days.